[18F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
[18F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study ; volume:13 ; number:1 ; day:5 ; month:4 ; year:2023 ; pages:1-10 ; date:12.2023
EJNMMI Research ; 13, Heft 1 (5.4.2023), 1-10, 12.2023

Creator
Kerstens, Vera S.
Fazio, Patrik
Sundgren, Mathias
Halldin, Christer
Svenningsson, Per
Varrone, Andrea
Contributor
SpringerLink (Online service)

DOI
10.1186/s13550-023-00974-7
URN
urn:nbn:de:101:1-2023082121051240924321
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
24.09.2025, 4:58 PM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Kerstens, Vera S.
  • Fazio, Patrik
  • Sundgren, Mathias
  • Halldin, Christer
  • Svenningsson, Per
  • Varrone, Andrea
  • SpringerLink (Online service)

Other Objects (12)

Microglial activation in Parkinson’s disease using [18F]-FEPPA

Microglial activation in Parkinson’s disease using [18F]-FEPPA

Proxy-analysis of the genetics of cognitive decline in Parkinson’s disease through polygenic scores

Proxy-analysis of the genetics of cognitive decline in Parkinson’s disease through polygenic scores

Development of a novel radioligand for imaging 18-kD translocator protein (TSPO) in a rat model of Parkinson’s disease

Development of a novel radioligand for imaging 18-kD translocator protein (TSPO) in a rat model of Parkinson’s disease

Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease

Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease

Parkinson

Parkinson

Parkinson

Parkinson

Objective measurement in Parkinson’s disease: a descriptive analysis of Parkinson’s symptom scores from a large population of patients across the world using the Personal KinetiGraph®

Objective measurement in Parkinson’s disease: a descriptive analysis of Parkinson’s symptom scores from a large population of patients across the world using the Personal KinetiGraph®

The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson’s disease

The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson’s disease

Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination

Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies

Occipital hypoperfusion and motor reserve in Parkinson’s disease: an early-phase 18F-FP-CIT PET study

Occipital hypoperfusion and motor reserve in Parkinson’s disease: an early-phase 18F-FP-CIT PET study

Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed

Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed

Related objects